MARI.VI AT Equity☆

Pricefull chart →

1Y −70.5% · Off 52W high −71.9% · Vol (1Y) 80.6%

Key fundamentalsfull statements →

Marinomed Biotech AG is a biopharmaceutical company operating in Austria, elsewhere in Europe, and internationally. Its lead candidates include Budesolv, in late-stage clinical development for allergic rhinitis, and Tacrosolv, in Phase II studies for inflammatory eye conditions, while Satiasolv is in preclinical work. The company also offers Solv4U for formulation development and biopharmaceutical testing services. Previously named Marinomed Biotechnologie GmbH, it adopted its current name in 2017 and is headquartered in Korneuburg, Austria.

Snapshot

Headline riskfull risk →

Peers

No same-industry peers in the universe for MARI.VI.